MYMinyoung Youn

Minyoung Youn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Minyoung Youn has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Human KIT Antibody Briquilimab Diminishes Anaphylactic Responses in Mice Expressing Chimeric Human‐Mouse KIT

    by Hye‐Sook Kwon, Song Eun Lee, Ajay Sharma, Minyoung Youn, Charles A. Chang, Andrew Wells, Andrea R. Romo, Allison Ji, Sara Ratia, Sambidhan Kattel, et al.


  • Top Cited Papers
    Open Access

    RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia

    by Tim Kong, Angelo B. A. Laranjeira, Christopher T. Letson, LaYow Yu, Shuyang Lin, Jared S. Fowles, Daniel A. C. Fisher, Sherwin Ng, Wei Yang, Fan He, et al.

    Myeloid malignancies are heterogenous disorders characterized by distinct molecular drivers but share convergence of oncogenic signaling pathways and propagation by ripe pro-inflammatory niches. Here, we establish a comprehensive transcriptional atlas across the spectrum of myeloproliferative neoplasms (MPN) and secondary acute myeloid leukemia (sAML) through RNA-sequencing of 158 primary samples encompassing CD34+ hematopoietic stem/progenitor cells and CD14+ monocytes. Supported by mass cytometry (CyTOF) profiling, we reveal aberrant networks of PI3K/AKT/mTOR signalling and NFκB-mediated hyper-inflammation. Combining ATAC-Seq, CUT&Tag, RNA-seq, and CyTOF, we demonstrate that targeting of ribosomal protein S6 kinase A1 (RSK1) suppresses NFκB activation and diminishes pro-inflammatory mediators including tumor necrosis factor (TNF) associated with MPN disease severity and transformation. We further evaluate a therapeutic approach utilizing a first-in-class RSK inhibitor, PMD-026, currently in Phase 2 development for breast cancer, for use in myeloid malignancies. Treatment with PMD-026 suppressed disease burden across seven syngeneic and patient-derived xenograft leukemia mouse models spanning the spectrum of driver and disease-modifying mutations. These findings uncover a therapeutic avenue for a conserved dependency across MPN and sAML.


  • Open Access

    Diamond Blackfan anemia is mediated by hyperactive Nemo-like kinase

    by M. C. Wilkes, K. Siva, J. Chen, G. Varetti, M. Y. Youn, H. Chae, F. Ek, R. Olsson, T. Lundbäck, D. P. Dever, et al.

    Diamond Blackfan Anemia (DBA) is a congenital bone marrow failure syndrome associated with ribosomal gene mutations that lead to ribosomal insufficiency. DBA is characterized by anemia, congenital anomalies, and cancer predisposition. Treatment for DBA is associated with significant morbidity. Here, we report the identification of Nemo-like kinase (NLK) as a potential target for DBA therapy. To identify new DBA targets, we screen for small molecules that increase erythroid expansion in mouse models of DBA. This screen identified a compound that inhibits NLK. Chemical and genetic inhibition of NLK increases erythroid expansion in mouse and human progenitors, including bone marrow cells from DBA patients. In DBA models and patient samples, aberrant NLK activation is initiated at the Megakaryocyte/Erythroid Progenitor (MEP) stage of differentiation and is not observed in non-erythroid hematopoietic lineages or healthy erythroblasts. We propose that NLK mediates aberrant erythropoiesis in DBA and is a potential target for therapy.


  • Open Access

    Erratum: DNA demethylation for hormone-induced transcriptional derepression

    by Mi-Sun Kim, Takeshi Kondo, Ichiro Takada, Min-Young Youn, Yoko Yamamoto, Sayuri Takahashi, Takahiro Matsumoto, Sally Fujiyama, Yuko Shirode, Ikuko Yamaoka, et al.


  • The π− mesonic decay rates on 12ΛC, 28ΛSi and ΛFe

    by Y. Sato, S. Ajimura, K. Aoki, H. Bhang, T. Hasegawa, O. Hashimoto, H. Hotchi, Y.D. Kim, T. Kishimoto, K. Maeda, et al.


  • H1(d,2p)nreaction at 2 GeV deuteron energy

    by J. Erohuml, Z. Fodor, P. Koncz, Z. Seres, C. F. Perdrisat, V. Punjabi, A. Boudard, B. Bonin, M. Garçon, R. Lombard, et al.

    The H1(d,2p)n deuteron breakup reaction was measured at 2 GeV deuteron energy in a kinematically complete experiment. Fivefold differential cross sections are given in a wide range of kinematical variables and analyzed in terms of impulse approximation and NN rescattering. The deuteron momentum density was determined and deviations were found depending on the value of the four-momentum transfer ‖t‖ in the scattering process. At low ‖t‖ the momentum densities are in good agreement with the impulse approximation whereas large discrepancies were found above q≊200 MeV/c when the four-momentum transfer was large. Various possible origins of the anomalous behavior at high q values are discussed.